Next Article in Journal
Music Therapy in Pain and Anxiety Management during Labor: A Systematic Review and Meta-Analysis
Previous Article in Journal
Left Ventricular Diastolic and Systolic Functions in Patients with Hypothyroidism
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effects of Storage Temperature and pH on the Antifungal Effects of Commercial Oral Moisturizers against Candida albicans and Candida glabrata

1
Denture Prosthodontics Restoration, Advanced Dentistry Center, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
2
Departments of Oral and Maxillofacial Prosthodontics, Field of Oral and Maxillofacial Rehabilitation, Advanced Therapeutic Course, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
3
Section of Dental Hygiene, Division of Clinical Technology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
*
Author to whom correspondence should be addressed.
Medicina 2020, 56(10), 525; https://doi.org/10.3390/medicina56100525
Submission received: 2 September 2020 / Revised: 30 September 2020 / Accepted: 2 October 2020 / Published: 7 October 2020
(This article belongs to the Section Dentistry)

Abstract

:
Background and objectives: Oral moisturizers have been used to treat dry mouth. This study aimed to investigate the effects of storage temperature and pH on the antifungal effects of oral moisturizers against Candida albicans and Candida glabrata. Materials and Methods: Thirty-one oral moisturizers and amphotericin B (AMPH-B) were stored at 25 and 37 °C for 1 week. Subsequently, they were added to cylindrical holes in 50% trypticase soy agar plates inoculated with C. albicans and C. glabrata (107 cells/ml). The antifungal effects were evaluated based on the sizes of the growth-inhibitory zones formed. Two-way analysis of variance was used to determine the effects of storage temperature and pH on the growth-inhibitory zones. Results: Significant differences in the effects of storage temperature and pH of the moisturizers were observed against C. albicans and C. glabrata. The growth-inhibitory zones of samples stored at 37 °C and with neutral pH were significantly larger than those stored at 25 °C and with acidic pH, respectively. The sizes of the zones formed by most of the oral moisturizers were larger than those formed by AMPH-B (concentration, 0.63 µg/ml). Conclusion: The antifungal effects of oral moisturizers against C. albicans and C. glabrata were affected by their storage temperature and pH.

1. Introduction

The number and detection rate of Candida are increased in the oral cavity and on the surface of dentures in patients with dry mouth due to decreased salivary secretion [1,2,3,4]. Candida co-aggregates with highly pathogenic bacteria and creates a bacterial reservoir [5,6] leading to oral candidiasis and denture stomatitis [3,5,6]. Oral candidiasis is an opportunistic infection caused by Candida albicans in approximately 80% of cases [7,8]. On the other hand, Candida glabrata has been detected in immunocompromised patients with head and neck cancer and HIV, and those with denture stomatitis [9,10,11]. However, an increase in the number of patients with C. glabrata infection and oral candidiasis has been reported recently [8,9,12,13,14]. Oral candidiasis caused by C. glabrata is intractable because C. glabrata has intrinsically low susceptibility and is able to easily become resistant to azole antifungal agents, thus making it difficult to treat [13,15,16].
Although antifungal agents are used to treat oral candidiasis and denture stomatitis, long-term use of antimicrobial agents with a broad antifungal spectrum should be avoided due to the emergence of drug-resistant strains [17]. Dry mouth is a chronic disease; consequently, it is important to select a drug that can be used continuously for a long time to treat the oral candidiasis that accompanies this condition [18]. Therefore, oral moisturizers with antifungal effects may be useful for the symptomatic treatment of dry mouth. A few studies on the antifungal effect of oral moisturizers have been conducted so far, and the results are inconsistent [19,20,21,22].
The optimum temperature and pH for the growth of Candida are lower than those required for other bacteria [23,24]. The heating of an antifungal drug (fluconazole) has been shown to significantly increase its ability to inhibit biofilm formation by C. albicans [25,26]. Generally, the pH of a substance changes depending on the temperature, but the pH of commercially available oral moisturizers varies greatly depending on the type of product [27]. Therefore, the storage temperature and pH of an oral moisturizer might influence its antifungal effect.
The purpose of this study was to examine the effects of storage temperature and pH on the antifungal effects of oral moisturizers against C. albicans and C. glabrata.

2. Materials and Methods

2.1. Samples

Thirty-one commercially available oral moisturizers (11 liquid- or spray-type and 20 gel-type) along with amphotericin B (AMPH-B, Sigma-Aldrich Japan, Tokyo, Japan), dimethyl sulfoxide (DMSO), and distilled water were used in this study. AMPH-B and distilled water were used as positive and negative controls, respectively. The final concentration of AMPH-B with dimethyl sulfoxide was 1.25–0.04 µg/ml (DMSO%; 99.50–99.98%). Table 1 (liquid or spray) and Table 2 (gel) present the details of the moisturizers used in this study. Unopened oral moisturizers were heated in a direct heat CO2 incubator (#310, Thermo Fisher Scientific KK, Tokyo, Japan) at 37 °C and a cool incubator (KMH-050, AS ONE Ltd., Osaka, Japan) at 25 °C, starting from 1 week before the experiment.

2.2. Evaluation of Antifungal Effects

C. albicans (JCM1537, Riken BRC, Tsukuba, Japan) and C. glabrata (JCM3699, Riken BRC, Tsukuba, Japan) were cultured in Tryptic Soy Broth (TSB: Becton, Dickinson and Company, France. 0.8% agar: CAG5858, WAKO, Japan) liquid medium (5 ml) at 37 °C for 24 h, respectively. C. albicans and C. glabrata at concentrations of 107 cells/ml (100 μl) were mixed with 5 ml of TSB agar media and inoculated on 50% TSA plates (TSB: 15g/l, 2% agar) [18]. After the hardening of the media, 20-µl samples were placed within cylindrical holes (diameter, 5 mm; depth, 5 mm) that were prepared in the TSA plates [18]. The diameters of the growth-inhibitory zones were measured after 24 h. The growth-inhibitory zones for each sample were obtained from five plates and the average value was measured.

2.3. pH Measurement

The pH values of the oral moisturizers with antifungal effect were measured with a glass electrode (9681S-10D, HORIBA, Kyoto, Japan) connected to a portable pH meter (D-72, HORIBA, Kyoto, Japan) at 25 and 37 °C. The pH meter had a measurement range of pH 0 to 14, resolution of pH 0.01, and measurement accuracy of pH ± 0.01. The pH meter was calibrated using three types of calibration standard solutions (pH 4.01, pH 7.00, and pH 10.01) before the actual pH measurements.
The pH electrode was inserted into an 8-ml tube (Sarstedt K. K., Tokyo, Japan) containing 4 ml of the sample and held for 2 min. The same sample was measured five times, and the average value was calculated. The pH values obtained were classified as acidic if <6.5, and neutral if ≥6.5 and <7.5.

2.4. Statistical Analysis

A Chi-square test was used to compare the categorical variables. A t-test was used to compare the variables between the Candida species. The effects of pH type (neutral or acid) and storage temperature (25 or 37 °C) on the sizes of the growth-inhibitory zones were evaluated using the analysis of variance (ANOVA) test. The sizes of the growth-inhibitory zones were analyzed using Tukey’s multiple comparisons test. All statistical analyses were performed using IBM SPSS Statistics 26 (Japan IBM, Tokyo, Japan), and the significance level was set a p < 0.05.

3. Results

3.1. Measurement Results of Each Moisturizer at 25 and 37 °C

Table 3 shows the size of the growth-inhibitory zone (mm) against C. albicans, pH value, and pH type of each sample at 25 and 37 °C. A total of eight oral moisturizers with antifungal effects against C. albicans, including two gel types and six liquid types, were observed. The average sizes of the growth-inhibitory zones of the liquid- and gel-type moisturizers were 7.66 and 8.72 mm at 25 °C, respectively, and 10.22 and 11.61 mm at 37 °C, respectively. The average pH value of the samples with growth-inhibitory zones against C. albicans at 25 °C was 6.78 for the liquid-type moisturizers and 6.38 for the gel-type moisturizers; the corresponding values at 37 °C were 6.45 and 6.41 for the liquid- and gel-type moisturizers, respectively. The proportion of moisturizers with an acidic pH was 56.3% (9/16).
Table 4 shows the size of the growth-inhibitory zone (mm) against C. glabrata, pH value, and pH type of each sample at 25 and 37 °C. A total of 12 oral moisturizers with antifungal effects against C. glabrata, including three gel types and nine liquid types, were observed. The eight moisturizers demonstrated antifungal effects against both C. albicans and C. glabrata. The average sizes of the growth-inhibitory zones for the liquid- and gel-type moisturizers were 12.24 and 11.68 mm at 25 °C, respectively, and 15.50 and 15.06 mm at 37 °C, respectively. The average pH value of the samples with growth-inhibitory zones against C. glabrata at 25 °C was 6.70 for the liquid-type moisturizers and 5.93 for the gel-type moisturizers; the corresponding values at 37 °C were 6.45 for the liquid-type moisturizers and 5.96 for the gel-type moisturizers. The proportion of moisturizers with an acidic pH was 66.7% (16/24).

3.2. Differences in Candida Species and Antifungal Effects of Oral Moisturizers

The upper part of Table 5 shows the number of growth-inhibitory zones against C. albicans and C. glabrata for each type of oral moisturizer. The results of the χ2 test indicated a significant difference in the number of growth-inhibitory zones and the Candida species, regardless of the type of oral moisturizer used. The lower part of Table 5 shows the mean size of the growth-inhibitory zone and mean pH value against C. albicans and C. glabrata. The size of the growth-inhibitory zone against C. albicans was significantly smaller than that against C. glabrata, and the pH value of the moisturizers that demonstrated an antifungal effect against C. albicans was significantly higher than that against C. glabrata (t-tests).

3.3. The Effects of pH Type and Storage Temperature on the Sizes of the Growth-Inhibitory Zones

Table 6 show the results of two-way analysis of variance (ANOVA) for the effects of the storage temperature and pH type of the oral moisturizers on the size of the growth-inhibitory zone of the oral moisturizer against C. albicans and C. glabrata, respectively. The results indicate storage temperature (A) and pH type (B) had significant effects on the sizes of the growth-inhibitory zones (p < 0.05) against both C. albicans and C. glabrata; however, the interaction between them (A × B) was not significant. The size of the growth-inhibitory zone against C. albicans was significantly larger at a storage temperature of 37 °C (11.26 mm) than that at 25 °C (8.64 mm) and was significantly larger in the neutral pH products (10.58 mm) than in the acidic pH products (9.33 mm). For C. glabrata, the size of the growth-inhibitory zone at 37 °C was significantly larger (15.30 mm) than that at 25 °C (12.03 mm); likewise, it was significantly larger in the neutral pH products (14.18 mm) than in the acidic pH products (13.15 mm).

3.4. Comparison of the Growth-Inhibitory Zones between Oral Moisturizers and AMPH-B

Comparisons of the sizes of the growth-inhibitory zones among the various concentrations of AMPH-B and oral moisturizers used against C. albicans and C. glabrata, respectively, are shown in Table 7 and Table 8. The value in the box represents the p-value of the Tukey test, and in the horizontal direction, * represents that the size of growth-inhibitory zone of AMPH-B was larger than that of the oral moisturizer, and # represents the opposite. The bold and italic values indicate that the size of the growth-inhibitory zones of the oral moisturizer is equal or greater than that of AMPH-B.
In Table 7, the gel-type moisturizer G presented with the largest the growth-inhibitory zone at 25 °C, larger than that observed with AMPH-B (concentration, 0.63 µg/ml); however, the sizes of the zones in the cases of most of the other moisturizers were the equal to or less than that observed with AMPH-B (concentration, 0.08 µg/ml). At 37 °C, the sizes of the growth-inhibitory zones were increased with all the moisturizers, and many of them were larger than those observed with AMPH-B at a concentration of 0.63 µg/ml.
As seen in Table 8, the gel-type moisturizer G presented with the largest growth-inhibitory zone against C. glabrata at 25 °C, larger than that observed with AMPH-B (concentration, 0.63 µg/ml); however, the sizes of the zones with the other moisturizers were equivalent to that observed with AMPH-B (concentrations, 0.31 µg/ml to 0.04 µg/ml). At 37 °C, the sizes of the growth-inhibitory zones of all the moisturizers were increased to those equivalent to or larger than that observed with AMPH-B (concentration, 0.63 µg/ml).

4. Discussion

It is important to avoid the risk of systemic infections, which can lead to poor quality of life in patients with dry mouth, due to the increased levels of Candida in the oral cavity and mucosal surfaces of dentures [1,2,3,4]. Although antifungal agents are prescribed for the treatment of oral candidiasis, azole antifungal agents are contraindicated in patients receiving anticoagulant therapy; moreover, long-term use of antifungal agents should be avoided due to the emergence of drug-resistant strains [17]. However, considering that oral moisturizers are routinely used for patients with dry mouth, the use of a moisturizer with antifungal effects might prove effective in reducing the risk of Candida infection. Therefore, this study comprehensively investigated the antifungal effects of commercially available oral moisturizers against C. albicans and C. glabrata and examined the effects of storage temperature and pH on the antifungal effects of these moisturizers.
It is not clear that the agar diffusion method, employed to test antifungal proficiency, accurately models in vivo activity. Since the agar diffusion method could be affected by differences in viscosity, differences in viscosity of oral moisturizer may affect differences in the zones of inhibition [28,29,30]. Additionally, a moisturizer stored at 25 °C should quickly ascend to a much higher temperature in the mouth. The concentration of AMPH-B used in this study was determined with reference to previous in vitro studies [18]. However, the in vitro results can be extrapolated in in vivo conditions with certain limitations.
Physical properties, such as viscosity, transpiration rate, and adhesive strength of oral moisturizers used for the symptomatic treatment of patients with dry mouth [1,2,18], have been studied previously [27,28,29]. However, reports on the antibacterial properties of these moisturizers are limited [18,19,20,21,22]. The efficacy of oral moisturizing jelly (OMJ) and a topical commercial gel (GC dry mouth gel) on Candida colonization and saliva properties was evaluated by a randomized controlled trial [22]. The results show that both OMJ and GC saliva gels could improve saliva pH and decrease the number of Candida species [22]. The current study was the first to comprehensively investigate the antifungal properties of commercially available oral moisturizers against C. albicans and C. glabrata.
In the present study, the antifungal effects observed against C. glabrata were higher than those observed against C. albicans, and the sizes of the growth-inhibitory zones against C. glabrata were significantly larger than those against C. albicans. Oral candidiasis is a fungal disease mainly caused by C. albicans [7,8]. However, an increase in the involvement of C. glabrata has been reported over the past few years [8,9,12,13,14]. The adhesive strength of C. glabrata to acrylic resin is twice that of C. albicans [7]; therefore, it is more frequently isolated from the mucosal surfaces of dentures in elderly patients [31]. C. glabrata cannot invade the epithelium by itself because it is a non-dimorphic yeast, but co-infection with C. albicans promotes invasion into the epithelium [9,32]. The proportion of C. glabrata resistant to azole antifungal agents is increasing [13]. In addition, there are reports that infection with C. glabrata alone or in combination with C. albicans is more resistant to azole antifungal agents than that with C. albicans alone [10,11]. In this study, the antifungal effects on C. albicans and C. glabrata were individually investigated. However, additional studies are required to examine the co-cultures of these species in the future.
The labels on oral moisturizers contain instructions about the storage of the product away from high temperatures and direct sunlight, but clear instructions about the appropriate storage temperature are not specified generally. In this study, the storage temperature of the oral moisturizers was set based on room temperature and body temperature. The heating of fluconazole at 39 °C was shown to significantly increase its ability to inhibit biofilm formation by C. albicans when compared to that at 37 °C [26]. Although it was not the same as the heating temperature of fluconazole, the sizes of the growth-inhibitory zones formed by moisturizers stored at 37 °C were significantly larger than those formed by moisturizers that were stored at 25 °C in the current study. This may be attributed to the fact that the optimum temperature for Candida growth is 25 to 30 °C, which is lower than that for other bacteria [23,24]. This difference may have affected the activity of the antifungal ingredients in the oral moisturizers.
In this study, the oral moisturizers with antifungal effect contained an egg yolk antibody against Candida, in addition to hinokitiol, whey protein, and lactoferrin [18,33]. The differences in the sizes of the growth-inhibitory zones between the different concentrations of AMPH-B and the various oral moisturizers were attributed to the different mechanisms of actions of the antifungal ingredients contained in the moisturizers. Moisturizer G, which had the highest antifungal activity, contained hinokitiol. Hinokitiol is obtained from Hiba (a type of cypress) and exerts high antibacterial activity by inhibiting the tricarboxylic acid cycle of the bacteria [18]. On the other hand, egg yolk antibody, which is included in gel-type moisturizers “H” and “N”, binds to the adhesion factor and the toxin produced by Candida, thereby inhibiting its adhesion to mucosal epithelial cells and inactivating the toxin [33]. Whey protein, which is present in the liquid-type moisturizer “c” and gel-type moisturizer “J”, should be used with caution in patients with a history of milk allergy [18].
The antifungal effects of oral moisturizers at temperatures other than those described in this study remain unknown because they have not been evaluated so far. The results of a study in which the antifungal properties of fluconazole were increased by heating it to 39 °C [26] suggest that it is necessary to investigate the antifungal properties of oral moisturizers stored at temperatures above 37 °C. However, if the oral moisturizer is stored at a high temperature for a long time, a deterioration in its quality may be expected. In a previous study, the antimicrobial activity of an oral moisturizer stored in an incubator at 37 °C for 8 h was significantly lower than that observed immediately after opening the package [18]. This result suggests that when heating the oral moisturizer, it is necessary to devise a heating method such as heating immediately before use.
The pH of saliva is reduced in patients with dry mouth [1,2,33]. Consequently, the pH is optimum for the secretion of aspartyl proteinase produced by Candida, which leads to an increase in its pathogenicity [34]. The detection of significantly larger growth-inhibitory zones in moisturizers with neutral pH compared to those with acidic pH in the current study corresponded with the fact that the optimum pH of Candida is 5.6, which is lower than that of other bacteria [21,24,35]. The critical pH values at which enamel dissolves range from 5.5 to 6.5, depending on the phosphate and calcium concentrations in saliva [36]. In the present study, a pH lower than 6.5 was defined as acidic based on the critical pH value when the concentrations of phosphate and calcium were high. According to the results of this study, the pH values of oral moisturizers with antifungal effects ranged from 3.46 to 7.29, but about 60% of them were more acidic than the critical pH value. These findings are largely consistent with the results of a survey of seven commercially available oral moisturizers [27]. Taken together, these results suggest that caution should be exercised when using oral moisturizers in dentulous patients with dry mouth because moisturizers with an acidic pH have low antifungal activity and the potential to erode teeth [27].
In this study, the number of oral moisturizers investigated greatly differed from those in past reports, which may be attributed to the product life cycle of the moisturizers. The product life cycle of oral moisturizers in Japan is short, and only 12 products that were used in a previous survey were used in the current study [18]. Oral moisturizers are used as self-care products for patients who complain of dry mouth and are purchased by individuals based on their preference. Therefore, it is necessary for medical staff to fully understand the symptoms of the patient and the characteristics of the oral moisturizer used, particularly regarding the selection and storage of the oral moisturizer. Furthermore, it is important to constantly update the information and provide appropriate advice on the selection and usage of these moisturizers.

5. Conclusions

Within the limitations of this in vitro study, our findings suggested that the antifungal effects of oral moisturizers against C. albicans and C. glabrata were affected by their storage temperature and pH.

Author Contributions

Conceptualization, M.M., K.H., and M.N.; methodology, M.M., K.H., and Y.N.; investigation, M.M., K.H., S.M., and Y.N.; Data curation, M.M., K.H., and Y.N.; supervision, M.N.; validation, T.S.; writing—original draft, M.M.; writing—review and editing, M.M., K.H., Y.N., T.S., S.M., and M.N. All authors have read and agree to the published version of the manuscript.

Funding

This work was partially supported by a Grant-in-Aid for Scientific Research (C- 18K09665).

Conflicts of Interest

The authors have no conflict of interest relevant to this article.

References

  1. Han, P.; Suarez-Durall, P.; Mulligan, R. Dry mouth: A critical topic for older adult patients. J. Prosthodont. Res. 2015, 59, 6–19. [Google Scholar] [CrossRef]
  2. Diaz-Arnold, M.; Marek, C.A. The impact of saliva on patients: A literature review. J. Prosthet. Dent. 2002, 88, 337–343. [Google Scholar] [CrossRef] [PubMed]
  3. Torres, S.R.; Peixoto, C.B.; Caldas, D.M.; Silva, E.B.; Akiti, T.; Nucci, M.; de Uzeda, M. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2002, 93, 149–154. [Google Scholar] [CrossRef] [PubMed]
  4. Murakami, M.; Nishi, Y.; Seto, K.; Kamashita, Y.; Nagaoka, E. Dry mouth and denture plaque microflora in complete denture and palatal obturator prosthesis wearers. Gerodontology 2015, 32, 188–194. [Google Scholar] [CrossRef] [PubMed]
  5. Nikawa, H.; Hamada, T.; Yamamoto, T. Denture plaque –Past and recent concerns. J. Dent. 1998, 26, 299–304. [Google Scholar] [CrossRef]
  6. Sumi, Y.; Miura, H.; Sunakawa, M.; Michiwaki, Y.; Sakagami, N. Colonization of denture plaque by respiratory pathogens in dependent elderly. Gerodontology 2002, 19, 25–29. [Google Scholar] [CrossRef] [PubMed]
  7. Luo, G.; Samaranayake, L.P. Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surface compared with Candida albicans. APMIS 2002, 110, 601–610. [Google Scholar] [CrossRef]
  8. Li, L.; Redding, S.; Dongari-Bagtzoglou, A.D. Candida glabrata, an emerging oral opportunistic pathogen. J. Dent. Res. 2007, 86, 204–215. [Google Scholar] [CrossRef]
  9. Rodrigues, C.F.; Silva, S.; Henriques, M. Candida glabrata: A review of its features and resistance. Eur. J. Clin. Microbiol. Infect Dis. 2014, 33, 673–688. [Google Scholar] [CrossRef] [Green Version]
  10. Redding, S.W.; Dahiya, M.C.; Kirkpatrick, W.R.; Coco, B.J.; Patterson, T.F.; Fothergill, A.W.; Rinaldi, M.G.; Thomas Jr, C.R. Candida glabrata is an emerging cause of oropharyngeal candidiasis inpatients receiving radiation for head and neck cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2004, 97, 47–52. [Google Scholar] [CrossRef]
  11. Redding, S.W.; Kirkpatrick, W.R.; Dib, O.; Fothergill, A.W.; Rinaldi, M.G.; Patterson, T.F. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Special Care Dent. 2000, 20, 178–181. [Google Scholar] [CrossRef] [PubMed]
  12. Coco, B.J.; Bagg, J.; Cross, L.J.; Jose, A.; Cross, J.; Ramage, G. Mixed Candida albicans and Candida glabrata populations associated with pathogenesis of denture stomatitis. Oral Microbiol. Immunol. 2008, 23, 377–383. [Google Scholar] [CrossRef] [PubMed]
  13. Kamikawa, Y.; Mori, Y.; Nagayama, T.; Fujisaki, J.; Hirabayashi, D.; Sakamoto, R.; Hamada, T.; Sugihara, K. Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013. BMC Oral Health 2014, 14, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Tati, S.; Davidow, P.; McCall, A.; Hwang-Wong, E.; Rojas, I.G.; Cormack, B.; Edgerton, M. Candida glabrata Binding to Candida albicans Hyphae Enables Its Development in Oropharyngeal Candidiasis. PLoS Pathog. 2016, 30, e1005522. [Google Scholar] [CrossRef] [Green Version]
  15. Sanita, P.V.; Mima, E.G.; Pavarina, A.C.; Jorge, J.H.; Machado, A.L.; Vergani, C.E. Susceptibility profile of a Brazilian yeaststock collection of Candida species isolated from subjects with Candida-associated denture stomatitis with or without diabetes. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 116, 562–569. [Google Scholar] [CrossRef] [Green Version]
  16. Song, Y.B.; Suh, M.K.; Ha, G.Y.; Kim, H. Antifungal susceptibility testing with etest for Candida species isolated from patients with oral candidiasis. Ann. Dermatol. 2015, 27, 715–720. [Google Scholar] [CrossRef] [Green Version]
  17. Dias, A.P.; Samaranayake, L.P.; Lee, M.T. Miconazole lacquer in the treatment of denture stomatitis: Clinical and microbiological findings in Chinese patients. Clin. Oral Investig. 1997, 1, 47–52. [Google Scholar] [CrossRef]
  18. Murakami, M.; Fujishima, K.; Nishi, Y.; Minemoto, Y.; Kanie, T.; Taguchi, N.; Nishimura, M. Impact of type and duration of application of commercially available oral moisturizers on their antifungal effects. J. Prosthodont. 2018, 27, 52–56. [Google Scholar] [CrossRef]
  19. Gil-Montoya, J.A.; Guardia-L´opez, I.; Gonz´alez-Moles, M.A. Evaluation of the clinical efficacy of a mouthwash and oral gel containing the antimicrobial proteins lactoperoxidase, lysozyme and lactoferrin in elderly patients with dry mouth—A pilot study. Gerodontology. 2008, 25, 3–9. [Google Scholar] [CrossRef]
  20. Güneri, P.; Alpöz, E.; Epstein, J.B.; Çankaya, H.; Ateş, M. In vitro antimicrobial effects of commercially available mouth-wetting agents. Spec Care Dentist. 2011, 31, 123–128. [Google Scholar] [CrossRef]
  21. Rhodus, N.L.; Bereuter, J. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren’s syndrome. J. Otolaryngol. 2000, 29, 28–34. [Google Scholar] [PubMed]
  22. Lam-Ubol, A.; Matangkasombut, O.; Trachootham, D.; Tarapan, S.; Sattabanasuk, V.; Talungchit, S.; Paemuang, W.; Phonyiam, T.; Chokchaitam, O.; Mungkung, O.O. Efficacy of gel-based artificial saliva on Candida colonization and saliva properties in xerostomic post-radiotherapy head and neck cancer patients: A randomized controlled trial. Clin. Oral Investig. 2020. [Google Scholar] [CrossRef] [PubMed]
  23. Yoshida, S.; Yanagi, Y.; Yoshikai, Y. Toda’s New Bacteriology, 34th ed.; Nanzando Company Limited: Tokyo, Japan, 2013; pp. 722–745. [Google Scholar]
  24. Sherris, J.C. Molecular Medical Microbiology. In An Introduction to Infectious Diseases, 2nd ed.; Elsevier Science Publishing Co. Inc.: New York, NY, USA, 1990; pp. 627–635. [Google Scholar]
  25. Jiang, Q.; Cross, A.S.; Singh, I.S.; Chen, T.T.; Viscardi, R.M.; Hasday, J.D. Febrile core temperature is essential for optimal host defense in bacterial peritonitis. Infect Immun. 2000, 68, 1265–1270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Cho, T.; Nagao, J.; Imayoshi, R.; Kodama, J.; Morotomi, T.; Kaminishia, H. In Vitro Efficacy of continuous mild heat stress on the antifungal susceptibility of Candida albicans biofilm formation. Biol. Pharm. Bull. 2012, 35, 1371–1373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Delgado, A.J.; Olafsson, V.G.; Donovan, T.E. pH and Erosive Potential of Commonly Used Oral Moisturizers. J. Prosthodont. 2016, 25, 39–43. [Google Scholar] [CrossRef]
  28. Okura, E.; Ishii, H.; Takamoto, Y.; Takayama, Y.; Makihira, S.; Kumagai, H.; Sasaki, M.; Taji, T.; Nikawa, H. Evaluation of physical properties of commercial mouth moisturizer. J. J. Dent. Mater. 2012, 31, 258–265. [Google Scholar]
  29. Murakami, M.; Nishi, Y.; Fujishima, K.; Nishio, M.; Minemoto, Y.; Kanie, T.; Nishimura, M. Impact of types of moisturizer and humidity on the residual weight and viscosity of liquid and gel oral moisturizers. J. Prosthodont. 2016, 25, 570–575. [Google Scholar] [CrossRef]
  30. Kano, H.; Kurogi, T.; Shimizu, T.; Nishimura, M.; Murata, H. Viscosity and adhesion strength of cream-type denture adhesives and mouth moisturizers. Dent. Mater. J. 2012, 31, 960–968. [Google Scholar] [CrossRef] [Green Version]
  31. Lockhart, S.R.; Joly, S.; Vargas, K.; Swails-Wenger, J.; Enger, L.; Soll, D.R. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J. Dent. Res. 1999, 78, 857–868. [Google Scholar] [CrossRef]
  32. Silva, S.; Henriques, M.; Hayes, A.; Oliveira, R.; Azeredo, J.; Williams, D.W. Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium. J. Oral Pathol. Med. 2011, 40, 421–427. [Google Scholar] [CrossRef] [Green Version]
  33. Takeuchi, S.; Motohashi, J.; Kimori, H.; Nakagawa, Y.; Tsurumoto, A. Effects of oral moisturising gel containing egg yolk antibodies against Candida albicans in older people. Gerodontology 2016, 33, 128–134. [Google Scholar] [CrossRef] [PubMed]
  34. AlmståhI, A.; Wikström, M.; Stenberg, I.; Jakobsson, A.; Fagerberg-Mohlin, B. Oral microbiota associated with hyposalivation of different origins. Oral Microbiol. Immunol. 2003, 18, 1–8. [Google Scholar] [CrossRef] [PubMed]
  35. Schaller, M.; Borelli, C.; Korting, H.C.; Hube, B. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005, 48, 365–377. [Google Scholar] [CrossRef] [PubMed]
  36. Du, H.; Huang, G. Environmental pH adaption and morphological transitions in Candida albicans. Curr. Genet. 2016, 62, 283–286. [Google Scholar] [CrossRef] [PubMed]
Table 1. Details of the liquid- and spray-type moisturizers used in this study.
Table 1. Details of the liquid- and spray-type moisturizers used in this study.
MaterialsCodeManufacturerMain/Active Ingredients
Stoppers foraSun Dental Co., Ltd.Water, Glycerin, Xylitol, Lysozyme, Lactoferrin
Oral Wet SpraybYoshida Co., Ltd.Water, Xylitol, Sodium benzoate, Hyaluronate sodium
ConCool Mouth RinsecWeltec Co., Ltd.Water, PG, Sorbitol, Xylitol, Lactoferrin, Whey protein
Pepti Sal Mouth WashdT&K Co., Ltd.Water, PG, Xylitol, Polyglycitol, Nisin, Lactoferrin
Wet Keeping MisteOral Care. Inc.Glycerin, Betaine, Xylitol, Methylparaben, Sodium citrate
Biotene Mouth WashfGSK Co., Ltd.Water, Glycerin, Xylitol, Sorbitol, Propylene glycol
Clean & Moisture SpraygTrife Inc.Water, Glycerin, Lactococcus culture extract, Ume extract
Lion Oral SprayhLion CorporationGlycerin, PG, Polyglutamic acid, Xylitol, l-menthol
Care Heart SprayiTamagawa Eizai Co., Ltd.Water, Glycerin, Xylitol, Sodium citrate
SMILE HONEY Gel SprayjNippon Zettoc Co., Ltd.Water, Glycerin, Propanediol, Hyaluronate sodium, Xylitol
Sunstar Gel SpraykSUNSTAR Co., Ltd.Water, Glycerin, Glycosyl trehalose, BG
Otsuka distilled waterwOtsuka PharmaceuticalDistilled water
Amphotericin BAMPH-BWakoPolyene antimycotic
Dimethyl sulfoxideDMSOSigma-Aldrich(CH3)2SO, CAS No. 67- 68- 5
Table 2. Details of the gel-type moisturizers used in this study.
Table 2. Details of the gel-type moisturizers used in this study.
MaterialsCodeManufacturerMain/Active Ingredients
Wet aidADent care. Inc. Water, Maltitol, Trehalose, BG, Hyaluronate sodium
Oral Moisturizer Ai GelBRyoka Dental. Inc. Water, Glycerin, Carboxymethyl cellulose, Xylitol
Oral AquagelCGC Co., Ltd.Diglycerine, Water, Carboxymethyl cellulose
Denture GelDKamemizu Chem. Ind.Maltitol, Water, Glycerin, Propylene glycol
Ulora GelEBEE BRAND MEDICO DENTAL.CO., LTD.Water, Glycerin, Xylitol, Sorbitol, Propylene glycol
Wet KeepingFOral Care. Inc.Water, Glycerin, Betaine, Xylitol, Hydroxyethyl cellulose
Refre-care GEN Otsuka PharmaceuticalWater, Glycerin, Hyaluronate sodium, Hinokitiol, Xylitol
SMILE HONEY Oral Clean GelHNippon Zettoc Co., Ltd.Water, Sorbitol, Glycerin, Xanthan gum, Dried egg yolk
SMILE HONEY Honey GelINippon Zettoc Co., Ltd.Honey, Xylitol, Sucralose, Lemon juice, Tea extract
ConCool Mouth GelJWeltec Co., Ltd.Water, Maltitol, Sorbitol, Glycerin, Xylitol, Whey protein
Oral Balance GelKGSK Co., Ltd.Glycerin, Water, Sorbitol, Xylitol, Hydroxyethyl cellulose
Mouth Moist LOsaki Medical Co., Ltd.Water, Glycerin, Cellulose gum, Hyaluronate sodium
Pepti Sal Gentle Mouth GelMT&K Co., Ltd.Glycerin, Polyethylene glycol, Xylitol, Water, Lactoferrin
Terumo Oral GelNNippon Zettoc Co., Ltd.Water, Sorbitol, Glycerin, Xylitol, Dried egg yolk, Maltitol
Mouth Pure Oral care gelOKawamoto CorporationWater, Glycerin, Betaine, Hyaluronate sodium,
Sodium polyacrylate
Butler Moisturizing Transparent GelPSUNSTAR Co., Ltd.Water, Glycerin, Sorbitol, Hydrogenated starch hydrolysate, Propylene glycol
Viva-JellwetQNippon Zettoc Co., Ltd.Water, Glycerin, Sodium alginate, Hydroxyethyl cellulose, Cetylpyridinium chloride
Clean & Moisture GelRTrife Inc.Glycerin, Water, Lactococcus culture extract, Ume extract
OKUCHI WO ARAU GELSNippon Shika Yakuhin Co., Ltd.Water, Glycerin, Hydroxyethyl cellulose, Hyaluronate sodium
Care Heart GelTTamagawa Eizai Co., Ltd.Water, Glycerin, Xylitol, Hydroxyethyl cellulose
Table 3. Mean and standard deviation of the growth-inhibition zone (mm), pH value, and pH type of the moisturizers against Candida albicans.
Table 3. Mean and standard deviation of the growth-inhibition zone (mm), pH value, and pH type of the moisturizers against Candida albicans.
25 °C 37 °C 25 °C 37 °C
CodeGIZ (SD)pH Value pH TypeGIZ (SD)pH ValuepH TypeCodeGIZ (SD)pH ValuepH TypeGIZ (SD)pH ValuepH Type
a0 0 A0 0
b0 0 B0 0
c8.01 (0.11)7.12 (0.11)Na10.45 (0.16)6.36 (0.01)AcC8.57 (0.12)7.29 (0.00)Na11.16 (0.11)7.10 (0.01)Na
d0 0 D0 0
e0 0 E0 0
f0 0 F0 0
g0 0 G11.55 (0.12)6.64 (0.00)Na15.00 (0.07)6.73 (0.00)Na
h0 0 H8.94 (0.12)5.62 (0.00)Ac11.39 (0.08)5.69 (0.00)Ac
i0 0 I0 0
j7.22 (0.11)6.44 (0.11)Ac9.98 (0.10)6.53 (0.00)NaJ0 0
k0 0 K0 0
w0 0 L0 0
M0 0
N0 0
O7.81 (0.08)6.40 (0.00)Ac10.58 (0.07)6.47 (0.00)Ac
P0 0
Q7.76 (0.11)5.86 (0.01)Ac10.68 (0.10)5.93 (0.00)Ac
R0 0
S7.66 (0.08)6.48 (0.00)Ac10.85 (0.03)6.53 (0.00)Na
T0 0
Average7.66 (0.43)6.78 (0.32) 10.22 (0.26)6.45 (0.08) 8.72 (1.33)6.38 (0.53) 11.61 (1.52)6.41 (0.47)
GIZ—growth-inhibition zone (mm); SD—standard deviation; pH type (Neutral—Na; Acid—Ac).
Table 4. Mean and standard deviation of the growth-inhibition zone (mm), pH value, and pH type of the moisturizers against Candida glabrata.
Table 4. Mean and standard deviation of the growth-inhibition zone (mm), pH value, and pH type of the moisturizers against Candida glabrata.
25 °C 37 °C 25 °C 37 °C
CodeGIZ (SD)pH Value pH TypeGIZ (SD)pH ValuepH TypeCodeGIZ (SD)pH ValuepH TypeGIZ (SD)pH ValuepH Type
a0 0 A0 0
b0 0 B0 0
c12.40 (0.07)7.12 (0.11)Na15.77 (0.05)6.36 (0.01)AcC10.32 (0.04)7.29 (0.00)Na14.57 (0.10)7.10 (0.01)Na
d0 0 D0 0
e0 0 E10.50 (0.07)3.58 (0.01)Ac14.57 (0.07)3.46 (0.00)Ac
f0 0 F0 0
g0 0 G15.61 (0.14)6.64 (0.00)Na18.58 (0.14)6.73 (0.00)Na
h12.36 (0.03)6.55 (0.01)Na15.89 (0.04)6.45 (0.00)AcH11.93 (0.07)5.62 (0.00)Ac14.93 (0.07)5.69 (0.00)Ac
i0 0 I0 0
j11.97 (0.06)6.44 (0.11)Ac14.84 (0.03)6.53 (0.00)NaJ0 0
k0 0 K0 0
w0 0 L11.41 (0.04)5.97 (0.00)Ac14.41 (0.04)6.06 (0.00)Ac
M0 0
N10.84 (0.06)5.54 (0.01)Ac14.33 (0.04)5.69 (0.00)Ac
O11.87 (0.03)6.40 (0.00)Ac14.52 (0.15)6.47 (0.00) Ac
P0 0
Q11.86 (0.04)5.86 (0.01)Ac14.86 (0.04)5.93 (0.00)Ac
R0 0
S10.77 (0.16)6.48 (0.00)Ac14.76 (0.16)6.53 (0.00)Na
T0 0
Average12.24 (0.20)6.70 (0.29) 15.50 (0.46)6.45 (0.07) 11.68 (1.49)5.93 (0.97) 15.06 (1.25)5.96 (0.98)
GIZ—growth-inhibition zone (mm); SD—standard deviation; pH type (Neutral—Na; Acid—Ac).
Table 5. Number of growth-inhibition zones against C. albicans and C. glabrata with each oral moisturizer (upper row) and sizes of growth-inhibition zones and pH values in C. albicans and C. glabrata (lower row).
Table 5. Number of growth-inhibition zones against C. albicans and C. glabrata with each oral moisturizer (upper row) and sizes of growth-inhibition zones and pH values in C. albicans and C. glabrata (lower row).
Type of Moisturizer C. Glabrata (+)C. Glabrata (−)Total p-Value
LiquidC. albicans (+)202
C. albicans (−)189
Subtotal 3811 0.04 *
GelC. albicans (+)606
C. albicans (−)31114
Subtotal 91120 0.00 *
TotalC. albicans (+)808
C. albicans (−)41923
Total121931 0.00 *
* p < 0.05 denotes significant difference: Chi-square test
Type of FungiMean GIZ (SD)95% CIp-valueMean pH value (SD)95% CIp-value
C. albicans9.86 (0.23)9.41–10.310.00 *6.45 (0.51)6.33–6.570.00 *
C. glabrata13.50 (0.19)13.13–13.86 6.07 (0.94)5.89–6.25
GIZ—growth-inhibition zone (mm); * p < 0.05 denotes significant difference: T-tests.
Table 6. Results of the analysis of variance test for C. albicans and C. glabrata.
Table 6. Results of the analysis of variance test for C. albicans and C. glabrata.
Sourced. f.Sum of SquaresMean Squaref-Valuep-Value
C. albicans
Temperature (A)1132.78132.7883.360.00 *a
pH type (B)130.1230.1218.910.00 *b
A × B11.461.460.920.34
Error76121.061.59
Total808082.16
C. glabrata
Temperature (A)1284.34284.34214.560.00 *c
pH type (B)128.2028.2021.280.00 *d
A × B11.681.681.270.26
Error116153.731.33
Total12022,374.42
a 37 °C (11.26 mm) > 25 °C (8.64 mm), b Neutral (10.58 mm) > Acid (9.33 mm), c 37 °C (15.30 mm) > 25 °C (12.03 mm), d Neutral (14.18 mm) > Acid (13.15 mm), * p < 0.05.
Table 7. Comparison of the sizes of the growth-inhibition zones between the different concentrations of AMPH-B and types of moisturizers used against C. albicans.
Table 7. Comparison of the sizes of the growth-inhibition zones between the different concentrations of AMPH-B and types of moisturizers used against C. albicans.
AMPH-B 1.25:
11.68 (0.30)
AMPH-B 0.63:
10.54 (0.15)
AMPH-B 0.31:
10.01 (0.09)
AMPH-B 0.16:
9.72 (0.32)
AMPH-B 0.08:
9.22 (0.15)
AMPH-B 0.04:
8.38 (0.16)
DMSO:
8.30 (0.17)
Liquid moisturizerc-25 °C:
8.01 (0.11)
0.00 *0.00 *0.00 *0.00 *0.00 *0.220.79
c-37 °C: 10.45 (0.16) 0.00 *1.000.00 #0.00 #0.01 #0.00 #0.00 #
j-25 °C:
7.22 (0.11)
0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *
j-37 °C:
9.98 (0.10)
0.00 *0.00 *1.000.350.00 #0.00 #0.00 #
Gel moisturizerC-25 °C: 8.57 (0.12)0.00 *0.00 *0.00 *0.00 *0.00 *0.900.35
C-37 °C: 11.16 (0.11)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
G-25 °C: 11.55 (0.12)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
G-37 °C: 15.00 (0.07)0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
H-25 °C: 8.94 (0.12)0.00 *0.00 *0.00 *0.00 *0.280.00 #0.00 #
H-37 °C: 11.39 (0.08)0.20.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
O-25 °C: 7.81 (0.08)0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *
O-37 °C: 10.58 (0.07)0.00 *1.000.00 #0.00 #0.00 #0.00 #0.00 #
Q-25 °C: 7.76 (0.11)0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *
Q-37 °C: 10.68 (0.10)0.00 *1.000.00 #0.00 #0.00 #0.00 #0.00 #
S-25 °C: 7.66 (0.08)0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *0.00 *
S-37 °C: 10.85 (0.03)0.00 *0.090.00 #0.00 #0.00 #0.00 #0.00 #
The value in the box represents the p-value of the Tukey test, and in the horizontal direction, * represents that the size of the growth-inhibitory zone of AMPH-B was larger than that of the oral moisturizer, and # represents the opposite. The bold and italic values indicate that the size of the growth-inhibitory zones of the oral moisturizer is equal or greater than that of AMPH-B.
Table 8. Comparison of the sizes of the growth-inhibition zones between the different concentrations of AMPH-B and types of moisturizers used against C. glabrata.
Table 8. Comparison of the sizes of the growth-inhibition zones between the different concentrations of AMPH-B and types of moisturizers used against C. glabrata.
AMPH-B 1.25:
15.97 (0.06)
AMPH-B 0.63:
13.46 (0.03)
AMPH-B 0.31:
11.53 (0.02)
AMPH-B 0.16:
11.26 (0.02)
AMPH-B 0.08:
10.54 (0.05)
AMPH-B 0.04:
9.77 (0.06)
DMSO:
9.37 (0.07)
Liquid moisturizerc-25 °C:
12.40 (0.07)
0.00 *0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #
c-37 °C: 15.77 (0.05)0.060.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
h-25 °C: 12.36 (0.03)0.00 *0.00 *0.00 *0.00 *0.00 #0.00 #0.00 #
h-37 °C: 15.89 (0.04)1.00.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
j-25 °C:
11.97 (0.06)
0.00 *0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #
j-37 °C:
14.84 (0.03)
0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
Gel moisturizerC-25 °C: 10.32 (0.04)0.00 *0.00 *0.00 *0.00 *0.03 *0.00 #0.00 #
C-37 °C: 14.57 (0.10)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
E-25 °C: 10.50 (0.07)0.00 *0.00 *0.00 *0.00 *1.00.00 #0.00 #
E-37 °C: 14.57 (0.07)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
G-25 °C: 15.61 (0.14)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
G-37 °C: 18.58 (0.14)0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
H-25 °C: 11.93 (0.07)0.00 *0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #
H-37 °C: 14.93 (0.07)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
L-25 °C: 11.41 (0.04)0.00 *0.00 *0.00 *0.610.00 #0.00 #0.00 #
L-37 °C: 14.41 (0.04)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
N-25 °C: 10.84 (0.06)0.00 *0.00 *0.00 *0.00 *0.00 #0.00 #0.00 #
N-37 °C: 14.33 (0.04)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
O-25 °C: 11.87 (0.03)0.00 *0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #
O-37 °C: 14.52 (0.15)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
Q-25 °C: 11.86 (0.04)0.00 *0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #
Q-37 °C: 14.86 (0.04)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
S-25 °C: 10.77 (0.16)0.00 *0.00 *0.00 *0.00 *0.01 #0.00 #0.00 #
S-37 °C: 14.76 (0.16)0.00 *0.00 #0.00 #0.00 #0.00 #0.00 #0.00 #
The value in the box represents the p-value of the Tukey test, and in the horizontal direction, * represents that the size of growth-inhibitory zone of AMPH-B was larger than that of the oral moisturizer, and # represents the opposite. The bold and italic values indicate that the size of the growth-inhibitory zones of the oral moisturizer is equal or greater than that of AMPH-B.

Share and Cite

MDPI and ACS Style

Murakami, M.; Harada, K.; Nishi, Y.; Shimizu, T.; Motoyama, S.; Nishimura, M. Effects of Storage Temperature and pH on the Antifungal Effects of Commercial Oral Moisturizers against Candida albicans and Candida glabrata. Medicina 2020, 56, 525. https://doi.org/10.3390/medicina56100525

AMA Style

Murakami M, Harada K, Nishi Y, Shimizu T, Motoyama S, Nishimura M. Effects of Storage Temperature and pH on the Antifungal Effects of Commercial Oral Moisturizers against Candida albicans and Candida glabrata. Medicina. 2020; 56(10):525. https://doi.org/10.3390/medicina56100525

Chicago/Turabian Style

Murakami, Mamoru, Kae Harada, Yasuhiro Nishi, Takaharu Shimizu, Sara Motoyama, and Masahiro Nishimura. 2020. "Effects of Storage Temperature and pH on the Antifungal Effects of Commercial Oral Moisturizers against Candida albicans and Candida glabrata" Medicina 56, no. 10: 525. https://doi.org/10.3390/medicina56100525

Article Metrics

Back to TopTop